

Ralf-Dieter Hofheinz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/465598/publications.pdf>

Version: 2024-02-01

84
papers

3,030
citations

257429

24
h-index

168376

53
g-index

91
all docs

91
docs citations

91
times ranked

3750
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2022, 8, e215445.	7.1	127
2	Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial).. <i>Journal of Clinical Oncology</i> , 2022, 40, 303-303.	1.6	1
3	Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210779.	3.2	21
4	ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 99-106.	1.7	7
5	Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care. <i>Molecular Oncology</i> , 2022, 16, 2042-2056.	4.6	8
6	FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 3750-3761.	1.6	28
7	Abstract 4018: Long-term response to Trastuzumab in patients with advanced gastric or gastroesophageal adenocarcinoma - A retrospective study. <i>Cancer Research</i> , 2022, 82, 4018-4018.	0.9	0
8	Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 263-273.	2.5	5
9	Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC study (AIO-KRK-0111). <i>International Journal of Cancer</i> , 2021, 148, 1428-1437.	5.1	2
10	Differential Effects of Sound Intervention and Rest on Cardiovascular Parameters in Cancer Patients: A Randomized Cross-over Trial. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542199523.	2.0	2
11	Blood Cholesterol and Outcome of Patients with Cancer under Regular Cardiological Surveillance. <i>Current Oncology</i> , 2021, 28, 863-872.	2.2	2
12	Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. <i>European Journal of Cancer</i> , 2021, 144, 281-290.	2.8	6
13	Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. <i>International Journal of Cancer</i> , 2021, 149, 1322-1331.	5.1	48
14	Analysis of end-of-life treatment and physician perceptions at a university hospital in Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	2.5	1
15	Gender aspects in cardiooncology. <i>European Journal of Public Health</i> , 2021, 31, 1170-1176.	0.3	2
16	Routine Oncology Treatment and Its Human Deficits. <i>Recent Results in Cancer Research</i> , 2021, 218, 233-244.	1.8	0
17	Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2021, 164, 223-231.	0.6	8
18	Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma. <i>Oncology</i> , 2020, 98, 16-22.	1.9	23

#	ARTICLE	IF	CITATIONS
19	Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 294.	7.1	12
20	Oncology Research and Treatment 2020: Past, Present, and Future. <i>Oncology Research and Treatment</i> , 2020, 43, 259-261.	1.2	0
21	Coprevalence and Incidence of Lung Cancer in Patients Screened for Abdominal Aortic Aneurysm. <i>Anticancer Research</i> , 2020, 40, 4137-4145.	1.1	5
22	Statement to an Insufficient Systematic Review on <i>Viscum album</i> L. Therapy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-9.	1.2	10
23	Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1416.	7.1	19
24	Height of Rectal Cancer: A Comparison between Rectoscopic and Different MRI Measurements. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-7.	1.5	8
25	Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. <i>Drugs in R and D</i> , 2019, 19, 267-275.	2.2	4
26	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019, 45, 139-154.	6.1	36
27	Study evidence confirms current clinical practice in refractory metastatic colorectal cancer: the ReDOS trial. <i>Lancet Oncology</i> , The, 2019, 20, 1036-1037.	10.7	8
28	Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing. <i>Molecular Oncology</i> , 2019, 13, 1669-1683.	4.6	8
29	Cancer patients and music: (prospective) results from a survey to evaluate potential complementary treatment approaches. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2141-2148.	2.5	4
30	Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 123, 101-111.	2.8	10
31	Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. <i>Journal of Clinical Oncology</i> , 2019, 37, 3212-3222.	1.6	333
32	Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score. <i>Cancer Medicine</i> , 2019, 8, 4169-4175.	2.8	6
33	Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 2282-2291.	5.1	21
34	A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 183-189.	6.4	38
35	PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study. <i>World Journal of Urology</i> , 2018, 36, 375-381.	2.2	4
36	Impact of adjuvant chemotherapy on patients with ypT0-2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital. <i>World Journal of Surgical Oncology</i> , 2018, 16, 156.	1.9	6

#	ARTICLE	IF	CITATIONS
37	Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial. <i>BMC Cancer</i> , 2018, 18, 369.	2.6	5
38	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3500-3500.	1.6	25
39	Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. <i>European Journal of Cancer</i> , 2017, 76, 1-7.	2.8	49
40	Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 102-113.	4.4	32
41	Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional QoLiTime™ study. <i>BJU International</i> , 2017, 119, 731-740.	2.5	3
42	AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 105061-105071.	1.8	10
43	mMRI at 3.0 T as an Evaluation Tool of Therapeutic Response to Neoadjuvant CRT in Patients with Advanced-stage Rectal Cancer. <i>Anticancer Research</i> , 2017, 37, 215-222.	1.1	12
44	Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-7.	1.5	1
45	Prognostic Impact of mRNA Expression Levels of HER1/4 (ERBB1/4) in Patients with Locally Advanced Rectal Cancer. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9.	1.5	2
46	Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9.	1.5	9
47	Reply to S. Iwase et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 392-392.	1.6	1
48	Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. <i>Oncologist</i> , 2016, 21, 1483-1491.	3.7	64
49	Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications. <i>Journal of Gastroenterology</i> , 2016, 51, 971-984.	5.1	19
50	Rectal cancer: Neoadjuvant chemoradiotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 629-639.	2.4	49
51	Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 1215-1222.	6.4	15
52	Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of β -catenin expression. <i>Oncology Letters</i> , 2016, 11, 2715-2724.	1.8	9
53	Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3524-3524.	1.6	9
54	Quality of life (QoL) and therapy management in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): Interim results of the noninterventional QoLiTrap-study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 681-681.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Nab-paclitaxel/gemcitabine first-line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin levels: Data from the German QoLiXane Pancreatic Cancer Registry.. Journal of Clinical Oncology, 2016, 34, e15739-e15739.	1.6	0
56	CoCStom trial: study protocol for a randomised trial comparing completeness of adjuvant chemotherapy after early versus late diverting stoma closure in low anterior resection for rectal cancer. BMC Cancer, 2015, 15, 923.	2.6	12
57	Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea. Radiation Oncology, 2015, 10, 30.	2.7	13
58	Adjuvant chemotherapy for rectal cancer. Lancet Oncology, The, 2015, 16, e154-e155.	10.7	6
59	Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. Journal of Clinical Oncology, 2015, 33, 2444-2449.	1.6	54
60	Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma. Expert Review of Anticancer Therapy, 2015, 15, 607-614.	2.4	1
61	Improving Patient Outcomes with Regorafenib for Metastatic Colorectal Cancer - Patient Selection, Dosing, Patient Education, Prophylaxis, and Management of Adverse Events. Oncology Research and Treatment, 2015, 38, 300-308.	1.2	14
62	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 979-989.	10.7	577
63	Workload and Quality of Life of Medical Doctors in the Field of Oncology in Germany - a Survey of the Working Group Quality of Life of the AIO for the Study Group of Internal Oncology. Oncology Research and Treatment, 2015, 38, 154-159.	1.2	11
64	Changing symptom burden in cancer patients: Does physician-patient communication cover physical, psychological and social discomfort? A Survey among 2009 German patients.. Journal of Clinical Oncology, 2015, 33, e17717-e17717.	1.6	1
65	Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 731-731.	1.6	0
66	MMP9, Cyclin D1 and β -Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro. Anticancer Research, 2015, 35, 3801-10.	1.1	2
67	Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. Oncology Reports, 2014, 32, 668-676.	2.6	8
68	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.. Journal of Clinical Oncology, 2014, 32, 3501-3501.	1.6	51
69	HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.. Journal of Clinical Oncology, 2014, 32, 4073-4073.	1.6	36
70	PROCAPP: A randomized, open-label phase III trial comparing mapisal and urea hand-foot cream as prophylaxis for capecitabine-induced hand-foot skin reaction (HFSR) in patients (pts) with gastrointestinal (GI) tumors or breast cancer. A study of the AIO Quality of Life Working Group.. Journal of Clinical Oncology, 2014, 32, 9631-9631.	1.6	1
71	Prognostic value of HER2 expression in patients with bladder cancer treated with radical cystectomy: A biomarker study.. Journal of Clinical Oncology, 2014, 32, e15515-e15515.	1.6	1
72	The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (The QoLiTax-Trial of the Arbeitsgemeinschaft Internistische Onkologie, AIO).. Journal of Clinical Oncology, 2014, 32, 9621-9621.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 337-345.	2.5	4
74	Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data. <i>European Journal of Cancer</i> , 2013, 49, 3149-3158.	2.8	145
75	Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. <i>The Cochrane Library</i> , 2013, , CD008107.	2.8	110
76	A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a metaanalysis. <i>Radiology and Oncology</i> , 2013, 47, 166-175.	1.7	53
77	Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3531-3531.	1.6	39
78	POWER: An open-label, randomized phase III trial of cisplatin and 5-FU with or without panitumumab (P) for patients (pts) with nonresectable, advanced, or metastatic esophageal squamous cell cancer (ESCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4158-TPS4158.	1.6	1
79	Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. <i>Lancet Oncology, The</i> , 2012, 13, 579-588.	10.7	428
80	First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 65-72.	2.5	79
81	Population-Based Patterns of Care in the First-Line Treatment of Patients with Advanced Esophagogastric Adenocarcinoma in Germany. <i>Onkologie</i> , 2010, 33, 10-10.	0.8	11
82	Cetuximab in Combination With Capecitabine, Irinotecan, and Radiotherapy for Patients With Locally Advanced Rectal Cancer: Results of a Phase II MARGIT Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1487-1493.	0.8	104
83	Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1384-1390.	0.8	96
84	Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 276-278.	2.3	29